Ascendis Pharma A/S (NASDAQ:ASND) Receives $256.73 Consensus Price Target from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned an average recommendation of “Buy” from the seventeen brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $256.7333.

Several equities research analysts have weighed in on ASND shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Ascendis Pharma A/S in a report on Wednesday, November 26th. Stifel Nicolaus upped their price objective on shares of Ascendis Pharma A/S from $254.00 to $256.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Bank of America lifted their target price on Ascendis Pharma A/S from $227.00 to $230.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $260.00 to $264.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Finally, Raymond James Financial initiated coverage on Ascendis Pharma A/S in a research report on Friday, October 17th. They set a “strong-buy” rating and a $271.00 price target on the stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ASND. Allianz Asset Management GmbH grew its position in Ascendis Pharma A/S by 144.7% in the second quarter. Allianz Asset Management GmbH now owns 9,300 shares of the biotechnology company’s stock valued at $1,605,000 after purchasing an additional 5,500 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Ascendis Pharma A/S during the 2nd quarter worth about $897,000. Vident Advisory LLC bought a new position in shares of Ascendis Pharma A/S in the 1st quarter valued at about $273,000. Goldman Sachs Group Inc. increased its position in shares of Ascendis Pharma A/S by 10.4% in the first quarter. Goldman Sachs Group Inc. now owns 585,581 shares of the biotechnology company’s stock valued at $91,269,000 after acquiring an additional 55,164 shares during the last quarter. Finally, Hantz Financial Services Inc. increased its position in shares of Ascendis Pharma A/S by 291.1% in the second quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 262 shares during the last quarter.

Ascendis Pharma A/S Trading Up 1.0%

Shares of ASND opened at $211.02 on Thursday. The stock has a market cap of $13.07 billion, a P/E ratio of -47.53 and a beta of 0.45. Ascendis Pharma A/S has a 1 year low of $118.03 and a 1 year high of $229.94. The stock’s 50-day moving average price is $206.14 and its two-hundred day moving average price is $194.43.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.76). The firm had revenue of $250.71 million during the quarter, compared to the consensus estimate of $246.91 million. As a group, equities analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.